The role of PKC and PKD in CXCL12 directed prostate cancer migration

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Cancer metastasis is a leading cause of cancer-related mortality.
• Therapeutic resistance in cancers necessitates novel treatment strategies.
• Chemokine signaling pathways, including those involving PKC and PKD, are implicated in cancer cell migration.

Purpose of the Study:

• To investigate the role of Protein Kinase C (PKC) and Protein Kinase D (PKD) in CXCL12-mediated PC3 prostate cancer cell migration.
• To determine the specific contributions of different PKC isoforms (atypical, classical, novel) and PKD to prostate cancer cell motility.

Main Methods:

• Utilized PC3 prostate cancer cell line.
• Administered inhibitors for PKC and PKD to assess their impact on cell migration.
• Monitored calcium release and cellular morphology changes in response to inhibitors.
• Quantified changes in cell area and migration rates.

Main Results:

• PKC and PKD inhibitors did not affect calcium release in PC3 cells.
• Both PKC and PKD inhibition reduced PC3 cell migration, with atypical PKCζ inhibition showing the most significant effect.
• Inhibition of classical and/or novel PKC isoforms resulted in a more rounded cell morphology.
• PKD inhibition led to prostate cancer cell elongation.
• PKCζ inhibition caused PC3 cell enlargement, suggesting actin cytoskeletal dysregulation.

Conclusions:

• Atypical PKCζ is a critical mediator of PC3 prostate cancer cell migration.
• PKC and PKD are involved in CXCL12-mediated migration, influencing cell morphology and motility.
• Understanding specific signaling protein roles in chemokine cascades is crucial for developing targeted anti-metastasis therapies.